Appearance
Disarming myeloid resistance in CAR T therapy.
Literature Information
| DOI | 10.1016/j.ccell.2025.06.003 |
|---|---|
| PMID | 40578358 |
| Journal | Cancer cell |
| Impact Factor | 44.5 |
| JCR Quartile | Q1 |
| Publication Year | 2025 |
| Times Cited | 0 |
| Keywords | CAR T cell therapy, resistance mechanisms, CSF1R, B cell lymphoma, immunotherapy |
| Literature Type | Journal Article |
| ISSN | 1535-6108 |
| Pages | 1392-1393 |
| Issue | 43(8) |
| Authors | John M Warrington, Nathan Singh |
TL;DR
Stahl et al. reveal that a CSF1R+ myelo-monocytic population impairs the efficacy of CAR T cell therapy in B cell lymphoma, highlighting a critical resistance mechanism. Their findings demonstrate that targeting CSF1R can enhance the effectiveness of CD19-targeted CAR T cells, suggesting a potential therapeutic strategy to improve treatment outcomes.
Search for more papers on MaltSci.com
CAR T cell therapy · resistance mechanisms · CSF1R · B cell lymphoma · immunotherapy
Abstract
Uncovering mechanisms of resistance to chimeric antigen receptor (CAR) T cell therapy for B cell lymphoma is of paramount importance. In this issue of Cancer Cell, Stahl et al. identify a CSF1R+ myelo-monocytic population that disrupts CAR T cell function and show that inhibition of CSF1R enhances efficacy of CD19-targeted CAR T cells.
MaltSci.com AI Research Service
Intelligent ReadingAnswer any question about the paper and explain complex charts and formulas
Locate StatementsFind traces of a specific claim within the paper
Add to KBasePerform data extraction, report drafting, and advanced knowledge mining
Primary Questions Addressed
- What specific mechanisms do CSF1R+ myelo-monocytic cells use to disrupt CAR T cell function?
- How might targeting the CSF1R pathway affect the overall immune response in patients undergoing CAR T therapy?
- Are there other myeloid populations besides CSF1R+ cells that contribute to resistance in CAR T therapy for B cell lymphoma?
- What clinical strategies can be implemented to enhance the efficacy of CAR T therapy by addressing myeloid resistance?
- How does the inhibition of CSF1R compare to other therapeutic approaches in overcoming resistance to CAR T cells?
Key Findings
Research Background and Objective
Chimeric antigen receptor (CAR) T cell therapy has emerged as a revolutionary treatment for B cell lymphoma. However, resistance to this therapy poses a significant challenge to its efficacy. The objective of the study by Stahl et al. is to identify the mechanisms underlying resistance to CAR T cell therapy, specifically focusing on the role of a CSF1R+ myelo-monocytic population in impairing CAR T cell function.
Main Methods/Materials/Experimental Design
The researchers employed a combination of in vitro and in vivo experiments to investigate the impact of the CSF1R+ myelo-monocytic population on CAR T cell therapy. The study involved the following key steps:
- Identification of CSF1R+ Population: Flow cytometry was used to isolate and characterize the CSF1R+ myelo-monocytic cells from B cell lymphoma models.
- Functional Assays: Co-culture experiments were conducted to assess the effects of CSF1R+ cells on CAR T cell activation and cytotoxicity.
- Inhibition Studies: The efficacy of CD19-targeted CAR T cells was evaluated in the presence and absence of CSF1R inhibitors.
- In Vivo Models: Animal models of B cell lymphoma were utilized to assess the therapeutic impact of combining CAR T cell therapy with CSF1R inhibition.
Key Results and Findings
- The study identified a significant population of CSF1R+ myelo-monocytic cells that were shown to inhibit the activation and cytotoxic function of CAR T cells.
- Inhibition of CSF1R resulted in enhanced CAR T cell efficacy against B cell lymphoma in both in vitro and in vivo settings.
- The presence of CSF1R+ cells correlated with poorer outcomes in patients undergoing CAR T cell therapy, highlighting their role in resistance mechanisms.
Main Conclusion/Significance/Innovation
The findings of Stahl et al. provide critical insights into the mechanisms of resistance to CAR T cell therapy in B cell lymphoma. The identification of CSF1R+ myelo-monocytic cells as a key inhibitory population offers a novel target for therapeutic intervention. By combining CAR T cell therapy with CSF1R inhibition, there is potential to improve patient outcomes and overcome resistance.
Research Limitations and Future Directions
- Limitations: The study primarily focuses on a specific subtype of B cell lymphoma, and further research is needed to determine the generalizability of these findings across different lymphoma types and patient populations.
- Future Directions: Future studies should explore the molecular pathways involved in CSF1R+ cell-mediated inhibition of CAR T cells. Additionally, clinical trials evaluating the safety and efficacy of CSF1R inhibitors in combination with CAR T cell therapy are warranted to translate these findings into clinical practice.
© 2025 MaltSci - We reshape scientific research with AI technology